Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs MasterCard Inc (MA) Price & Performance

IDEXX Laboratories, Inc.Trade
MasterCard IncTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs MasterCard Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571.67 (market cap $46.22B), while MasterCard Inc trades at $557.51 (market cap $491.83B). The key difference: MasterCard Inc is far larger — about 10.6× IDEXX Laboratories, Inc.'s market cap, and MasterCard Inc pays a 0.62% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

IDXXMA
Market Cap
$46.22B$491.83B
Sector
HealthConsumer Cyclical
52-Week High
$766.68$598.96
52-Week Low
$526.44$471.55
Enterprise Value
$47.12B$504.86B
Volume
4,635,698
Dividend Yield
0.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.

Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.

MasterCard Inc

Mastercard (MA) trades at $563.17, showing stability with a slight 0.04% daily gain. The stock exhibits strong fundamentals, with Q2 2026 EPS beating expectations at $5.04 versus $4.77, and maintains robust profitability with a 46.34% net income margin. Technical indicators signal a bullish trend, supported by moving averages, while analyst consensus is overwhelmingly positive with a $660.85 price target. Recent news highlights institutional acquisitions and strategic initiatives in AI and digital inclusion.

Outlook remains favorable driven by consistent earnings beats and revenue growth, though risks include competitive pressures from emerging payment technologies like stablecoins and high valuation multiples. The stock presents a growth opportunity with solid institutional backing, but investors should monitor execution on innovation and macroeconomic factors affecting consumer spending.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA